Event-Driven Stocks

Barinthus Biotherapeutics plc.

BRNSNasdaq

Healthcare · Pharmaceutical Preparations · X0 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 2 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$0$15.0M$802,000$44.7M$268,000$4.8M
Operating income−$70.6M−$68.0M−$83.9M−$4.0M−$45.2M−$20.0M
Net income−$66.4M−$61.1M−$73.3M$5.3M−$50.9M−$17.7M
Total assets$98.2M$160.3M$214.5M$270.2M$280.7M$50.7M
Total liabilities$23.9M$30.2M$27.5M$27.0M$28.2M$53.8M
Equity$74.2M$130.0M$186.8M$242.9M$252.1M−$36.9M
EPS (diluted)$-1.64$-1.55$-1.91$0.14$-1.96$-2.24
Shares out.40.3M38.9M38.3M37.2M37.2M8.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−89.5%
Return on assets
−67.7%
Return on capital (ROCE)
−80.0%
Liabilities / assets
24.3%
Debt / equity
0.32×
Book value / share
$1.84
Revenue growth (YoY)
−100.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-7.14distress
Accruals / assets
−18.8%clean
Piotroski F-Score
1/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
42
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 2 warning● 2 good
  • Altman Z″ in the distress zone
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202614,3371.0+85.2%
Apr 30, 20267,7421.0-6.0%
Apr 15, 20268,2361.0-21.3%
Mar 31, 202610,4691.0+101.0%
Mar 13, 20265,2081.0-35.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)